Current drug use does not hinder treatment of hepatitis C virus

WASHINGTON — Active IV or prescription drug use did not affect attainment of sustained virologic response when treatment adherence for hepatitis C virus was already variable, according to a poster presented at The Liver Meeting.“These observations show that the more important factor in terms of predicting treatment outcome is whether the patient is compliant with therapy, not whether they’re concurrently using substances,” Tiberiu Moga, MD, a gastroenterologist at Indiana University Health, said in the presentation.In a single-center retrospective cohort study, MogaRead More